ImmunoTech Biopharm Ltd (HKG: 6978), a specialist in chimeric antigen receptor T-cell (CAR-T) therapies based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its aT19 injection. The treatment is designed as a sequential therapy for patients under the age of 25 with relapsed refractory B-cell-derived acute lymphoblastic leukemia (B-ALL) to prevent recurrence of CD19 positive cells.
The active ingredient of the aT19 injection is autologous T cells that have been genetically modified to express CD19. The introduced gene structure encodes for the human CD19 protein. By injecting CAR-T-19 and subsequently infusing the aT19 injection, it may be possible to reactivate CAR-T cells, reinitiate their proliferation, and induce a greater number of immune memory cells. This approach aims to increase the likelihood of eliminating minimal residual CD19 positive tumor cells and preventing disease recurrence. Through multiple exposures to the CD19 antigen, the number of CAR-T cells with immune memory function is also expected to increase. This would extend the immune surveillance duration of CAR-T cells and reduce the likelihood of recurrence of CD19 positive tumors.- Flcube.com
